MF-8 Eighth Microfluidics Consortium

MF-8.4

(Closed Meeting - Open Meeting – Day Delegates + Members),

June 22nd and 23rd Boston, MA USA

Final Version

Agenda

Delegate List

Speaker Profiles

Table-top Demonstrations

Hotel and Travel Recommendations

Eighth Microfluidics Consortium

The Eighth Microfluidics Consortium brings together current and future stakeholders from across a wide range of backgrounds with a shared interest in facilitating the growth of the industry through better understanding of the challenges, opportunities and choices which it faces.

Our current membership includes: CEA (F) ;EV Group (A) ; Fluidic Analytics (UK) ; Philips (NL); Micronit (NL); Danaher (USA); Corning (USA) ; Dolomite (UK) ; Fluigent ; Fraunhofer (D) and University College Dublin (EI); Lonza (CH) ; Plastic Design Corporation(USA); Philips (NL); IMT (CH), Labcyte (US) ; Qiagen (D) and University of Cambridge (UK).

We organize closed meetings for our members on both sides of the Atlantic where we seek to promote our mission “to grow the market for microfluidics enabled products and services” by

- Finding shared interest across the landscape of applications - Championing modularity and standards where appropriate - Engaging with key industry influencers

While helping our members to do deals along the way.

With the support of MIT on this occasion as well as our closed session on June 22nd we are also reaching out to selected guests in North America and beyond our membership in an Open Meeting on June 23th seeking to engage them in our vision, projects and thinking.

June 22nd Day Closed Day (MF8 Members only) The Bush Room, 10-105 (Building 10,

Room 105) is located in the Infinite Corridor on MIT’s campus see location details in the Appendix

10:00 Arrivals and Registration

10:30 Welcome / Introductions

11:00 Working Session 1 : Organ on a Chip

This session will take forward the MF8 Consortium’s work on supporting the development of

infrastructure for Cell/Tissue/Organ on a Chip systems

Murat Cirit MIT Translational Centre for Tissue Chip Technologies

“Organ on a Chip Technologies and where TC2T can help”

Murat Cirit, PhD, is a Research Scientist at MIT & director of the Translational Systems Pharmacology Team and System Integration Task in the DARPA-PhysioMimetics program (“Human Physiome on a Chip”) led by Linda Griffith. MIT and various institutions collaborate in creating a platform that supports ten interacting micro-physiological systems (MPS) and associated sensors for drug testing. Murat completed his PhD at NCSU focusing on systems biology of growth factor-mediated signal transduction pathways. After completion of his PhD, he worked in the pharmaceutical industry focusing on preclinical drug discovery for oncology. He brings an interdisciplinary and systematic approach through his extensive experimental knowledge and computational modeling with an understanding of biological, physiological, and physical processes. His main

research experience is systems pharmacology, systems biology, applied tissue engineering, cell biology and signal transduction networks. His current focus as the scientific lead is integrating various scientific fields to build interacting MPSs by interfacing platform engineering & tissue engineering for pharmacology studies.

“Vision and Opportunities for Organ on a Chip” Expert Witness Presentation Chris Hinojosa Emulate Bio

Emulate Inc. is a privately held company that creates living products for understanding how diseases, medicines, chemicals, and foods affect human health. Our Human Emulation System sets a new standard for recreating true-to-life human biology and is being used to advance product innovation, design, and safety across a range of applications including drug development, agriculture, cosmetics, food, and chemical-based consumer products. Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio

for the Organs-on-Chips technology and related systems. Emulate continues to develop a wide range of Organ-Chips and disease models through collaborations with industry partners and internal R&D programs. Emulate is also working with clinical partners to produce Organ-Chips personalized with an individual patient’s stem cells, for applications in precision medicine and personalized health.

Round Table Discussion: “How can we work together and help to enhance / accelerate the Tissue

Chip Technologies agenda?” Facilitated by Peter Hewkin

Including Contributions from:

- Lucie Low (National Center for Advancing Translational Sciences; MPS Programme Director;

Methesda Maryland)

- Kristin Fabre (Astra Zeneca Microphysiological Systems Lead – Drug Safety and Metabolism)

- MF 8 Members

13:00 Lunch Networking

13:30 Working Session 2 : Beyond Healthcare – responding to member interests the

consortium is reaching out to new industries. Here are some tasters!

Data

As requested by members after our meeting with IBM in Zurich we are

reaching deeper into the world of DNA data storage. Victor Zhirnov of the

Semiconductor Research Corporation has been championing this work on

behalf of the chip industry and will share his views of opportunities and

challenges.

Beauty

We are delighted to be enaging with Anil Achyuta who used to be a

researcher for Shashi Murthy and is now a technology talent scout for L’Oreal

based in Boston.

14:15 Working Session 3 : Microfluidics Hot Seat

Pitches from early stage microfluidics enabled

companies seeking to engage with the MF8 Consortium

Monika Weber Fluid-Screen

In 2015, how do scientists test the water supply to see if it’s contaminated with dangerous bacteria (e.g. E. coli) after runoff from heavy storms has overwhelmed the capacity of the treatment plant? How does the QA team in a food-processing plant assure that the latest batch of hot dogs is safe? How do physicians determine whether their patients’ infections are really bacterial rather than viral so they don’t prescribe antibiotics unnecessarily, thus contributing to the emerging “super-bug” crisis − resistant strains of bacteria? Pretty much the same way scientists have been doing it for more than 100 years.

Since the early 20th century, the standard method to detect dangerous bacteria has been to collect a sample, send it out to a lab, and wait 24 to 48 hours to grow a culture and report results. Fluid-Screen aims to change all that so that QA scientists and clinicians have the critical results they need where and when they need them to assure product quality, public health, and safety − or make better, more-informed treatment decisions.

The company has developed a breakthrough hand-held bacterial detection and identification system that provides rapid (~30-minute) results for applications ranging from municipal water quality assurance through agricultural and manufacturing processes to point-of-care diagnostics.

Roshan Kumar HiFiBio

Our unique platform utilizes droplet microfluidics for high throughput, single-cell, function-based screening of entire antibody secreting B-cell populations. Following single-cell-specific barcoding and next-generation sequencing, we generate paired V-gene sequences from the sorted B-cells. These target specific V-gene repertoires are then efficiently and rapidly converted to antibodies, speeding up the process of drug candidate selection. Thanks to the physical containment and flexibility of microdrops, we can apply virtual any known bioassay for measuring the functional activity of each secreted antibody. These unique features of our fully integrated platform provide a novel and powerful solution to find antibody drugs against complex targets.

15:30 Planning / Way Forward

16:00 Lab Visit – to the TC2T Lab The visit will be in our tissue chip testing center, where we will show

various tissue chip technologies from different labs. Facilitated by: Murat Cirit, Emily Geischenker and Catherine

Communal

Why Tissue Chips Matter

Approximately 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic — despite promising pre-clinical studies in animal and cell models. Tissue chips are a newer, human cell–based approach to this challenge. The chip devices may enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies.

Eliminating toxic and/or ineffective drugs earlier in the development process would save time and money. These human tissue chips also could teach us a great deal about disease progression, enabling researchers to better prevent, diagnose and treat disorders. Learn more about the Tissue Chip for Drug Screening program.

June 22nd Evening Joint Reception with FluidicMEMS

Note this event is also open to Day Delegates who have registered for the Open Day on June 23th. Open

Day delegates will be automatically registered and receive their entry tickets by email.

Location: 700 Main Street (See Logistics Section below for Map)

Jointly Sponsored by:

FluidicMEMS

This is an opportunity for Members of the MF8 consortium to network with our colleagues and good friends

from FluidicMEMs (Cadet Network) over drinks/buffet.

6:00 pm Doors Open

Networking, Drinks and Buffet

7:00 pm Address from Paul Blainey (Assistant Professor MIT)

Prof. Blainey completed his undergraduate degrees in Mathematics and

Chemistry at the University of Washington and a MA in Chemistry from Harvard

University. Paul Blainey continued his doctoral studies in Physical Chemistry at

Harvard University under the joint supervision of Profs. Xiaoliang Sunney Xie

and Gregory L. Verdine. He held a postdoctoral appointment at Stanford

University where he developed high-throughput microoptofluidic methods for

whole-genome amplification of DNA from individual, uncultivated microbial cells

in Prof. Stephen Quake’s laboratory. Paul joined MIT as an Assistant Professor

of Biological Engineering in 2012.

9pm Close

June 23rd Open day, Open to non-member day-delegates

Location: On June 23 we will be in NE 47-189 (Building 47, Room 189), is located in Tech Square, in

Kendall Square (see details in the Logistics Section of this document)

Open Day Delegates register and pay here. http://www.cfbi.com/mf74paymentpage.htm Table-top demos will be on show in the networking area from the following MF8 member organisations:

9:00 Registration, Networking, Table-Top Demos

9:30 Welcome and Introduction to the MF8 Consortium - Peter Hewkin

(Centre for Business Innovation)

Peter Hewkin has led the MF8 consortium for 8 years and is responsible for the

delivery of its mission to grow the market for Microfluidics enabled products and

services. He will describe the processes which the consortium uses, the successes

which it has achieved and the ideas it has for the future.

10:00 Session 1 – Manufacturing Options

In this session we will compare and contrast manufacturing options for Microfluidic Devices highlighting

performance, batch size, regulatory and economic implications. Members of the MF8 consortium will be

available at their table-tops with samples to talk about their options and possibilities

Fraunhofer (D / US) Alexis Sauer Budge: The Fraunhofer Center for

Manufacturing Innovation (CMI) conducts advanced research and development and

engineers solutions for a broad range of industries, including biotechnology,

photonics, manufacturing, and renewable energy. Engineers, scientists, faculty, and

students at our Center transform emerging research into viable technology solutions

that meet the needs of both domestic and global clients. Our services include product

and device development, high precision automation systems, and laboratory assays &

instruments.

“Fluidic Factory: Additive Manufacture” - Maxime Drobot head of products

Dolomite Microfluidics (UK / US).

Maxime will describe how prototype microfluidics chips can be created using additive

manufacturing techniques in your own laboratory.

Discussion: What option is right for me? And why?

11:00 Break, coffee, networking, table top demos

11:30 Session 2 Latest Research and Applications for Microfluidics

Droplets in free Air - Luke Ghislain : Labcyte (US)

Ultrasonic droplet ejection for liquid handling is robust and mature technology capable of precise and accurate transfers of almost any fluid between microplates at 2.5 and 25 nanoLiter granularity. But this technology still has plenty of room for growth: entirely new applications are now in development utilizing ultrasonic droplet ejection directly into a “reader”. One example is Acoustic Mist Ionization (AMI) for direct sample loading in Mass Spectrometry where we use ultrasonics to generate an electrically charged droplet cloud similar to Electrospray Ionization (ESI). This approach offers sub-second sampling, zero cross-talk, low sample consumption and kinetic measurements. An automated High Throughput Screen of more than 2 Million

compounds against a biologically important epigenetic target was recently completed.

Tools for Protein Scientists - Andrew Lynn : Founder, Fluidic Analytics (UK)

Proteins are the building blocks of life. They form the key components of cells, co-ordinate crucial biochemical processes and carry out the chemical reactions that allow the biological world to function.

By developing products that make protein characterisation faster, more precise, more convenient, more cost-effective and more accurate, Fluidic Analytics is striving to help scientists, healthcare providers and people everywhere to understand the world around them better.

12:30 Session 3 Major Funded Organ on a Chip Projects

“Progress update” - Murat Cirit MIT

Murat will present the latest public domain status from :

- DARPA (human body on a chip) and - NCATS (translational center of tissue chip technologies

Systematic Characterization of Microphysiological Systems (MPS)

A large percentage of drug candidates fail at the clinical trial stage due to a lack of efficacy

and unacceptable toxicity, primarily because the in vitro cell culture models and in vivo animal

models commonly used in preclinical studies provide limited information about how a drug will affect human

physiology. The need for more physiologically relevant in vitro systems for preclinical efficacy and toxicity testing has

led to a major effort to develop “Microphysiological Systems (MPS)” based on engineered human tissue constructs.

The MPS development process requires an initial assessment of viability and functionality, followed by an examination

of the MPS response to various stimuli, including drugs, toxins, and disease-related cues. These extensive

development efforts take place mainly in the developer's lab, and the reproducibility of the MPS results are rarely

assessed by an independent research group or transferred to industry partners for use in drug development. Although

there is a need for more physiologically-relevant preclinical testing technologies, the transition of MPS technologies

from academia to industry remains challenging. Successful transfer and deployment of MPS technologies requires

quantitative characterization and validation of the systems, preferably by an independent and unbiased external

testing facility. The Translational Center of Tissue Chip Technologies is to fill this gap between academic research and

development and industrial application of MPS technologies The Translational Center for Tissue Chip Technologies

combines a holistic and mechanistic approach—based on quantitative systems pharmacology (QSP)—that combines

quantitative experimental biology, computational biology, and biostatistics to achieve unbiased characterization of

these complex systems and translation of experimental insights to clinical outcomes.

13:15 Lunch, networking, table top demos

14:15 Session 4 Operational Techniques for Microfluidics

“Latest Products for Organ on a Chip and for Flow Control”– Anne Le-Nel, CSO Fluigent (F)

Anne will present to MF8 delegates the fluigent’s most recent work on Organ on a Chip as well as new disruptive flow control product See: http://www.fluigent.com/product/flow-ez/.

“Technologies to integrate sample to insight” – Jerzy Olejnik , Head of MDx technologies Qiagen (USA)

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a partnership with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

“micro- and nanostructured surfaces induced neuronal differentiation of mesenchymal

stem cells” - Claudia Skazik-Voogt. Fraunhofer-Institut für Produktionstechnologie IPT (D)

Nano-scale structural patterns are important hallmarks of the neuronal microenvironment in vivo. Cultivation of pluripotent stem cells or neuronal precursor cells on artificial nano-structures provides topographical cues directing cellular alignment and extension. Moreover, resulting physical load transfers tensile forces to the nucleus and influence signaling pathway, inducing neuronal lineage gene expression.

Mesenchymal stem cells (MSC) are of particular interest for regenerative medicine and exhibit a higher plasticity than previously anticipated. When cultured

under appropriate conditions, MSC do not only differentiate along mesodermal lineages, but also show upregulation of endo- and ectodermal lineage markers including those usually expressed on neurons.

In this study Polydimethylsiloxane (PDMS) micro-structured surfaces were used to induce neuronal marker expression in human adipose tissue-derived mesenchymal stem cells (AD-MSC). AD-MSC cultivation on these surfaces induced extension and alignment of cellular processes, while increased expression of neurofilament and β-tubulin III were confirmed on gene and protein levels as compared to standard (flat surfaces) cultivation conditions.

Our results indicate that directed nano-structures might regulate AD-MSC differentiation in vitro. This is of relevance for regenerative medicine since such nano-structures could be used for pre-differentiation

towards neuronal differentiation lineages, provide a novel tool for damaged neuronal tissue reconstitution, or for production of patient-specific neural cells

“scale-up of droplet manufacturing using a flexible mutli-channel and multi-chip approach” – Maxime

Drobot Head of Products Dolimite Microfluidics (UK)

Telos® is a revolutionary high-throughput microfluidic system which allows

production of up to a tonne of highly monodisperse droplets, particles or emulsion a

month

CellencTM: Microfluidic cell encapsulation platform: from 3D cell culture to cell therapy

Florence Rivera CEA-LETI-HEALTH (Fr) CellencTM is an automated microfluidic platform for cell encapsulation developed at CEA-

LETI. Such encapsulated cells may be used for various applications such as 3D cell culture or

cell therapy. Technologies and applications of such platform will be introduced.

CEA-LETI-HEALTH is one of the division of the CEA-LETI, a French research-and-technology

organization motivated on creating value and innovation through technology transfer to its

industrial partners. CEA- LETI- Health Division focuses on the development of micro-

nanotechnologies for applications in the fields of medical imaging, security, in vitro

diagnostic, nanomedicine, medical devices and environment monitoring. These activities

cover the design, integration and qualification of systems comprising sensors, actuators, analog front end

electronics, and acquisition system, signal processing algorithms, data management and control software.

Circa 15:45 Wrap-up, what have we learned? and Details of next meeting (Cambridge UK

Oct tbc)

16:00 Close

Open Day Delegate List (MF8 members in Bold)

Name Surname Organisation

Justin Abramson Pall

Abu Zayed Badruddoza MIT

Paul Blainey MIT

Julian Burke Leica Microsystems

Darryl Brousmiche Waters Corp

Monica Brivio Micronit

Conor Burke FPC@DCU

Julian Burke Leica Microsystems

Murat Cirit MIT

Jennifer Coggan Millifluidica

Tom Douglas

Curtis Densmore

Northeastern Boston University

Salil Desai Phenomyx

Steve DeWaters Volpi

Luke Ghislain Labcyte

Martin Eibelhuber EV Group

Kristin Fabre Astra Zeneca

Ye Fang Corning

Erin Graceffa Fluigent

Sunil Gangadharan IMEC

Richard Gray Dolomite

Kent Harv MIT

Roshan Kumar HiFiBio

Tina Haase MIt

Matt Heim Mettler Toledo

Peter Hewkin CfBI

David Christopher

Henderson Hinojosa

New Scale Technologies Emulate

Beatrice Icard CEA

Sasan Jalili Wyss / Harvard Medical School

Fatemeh Sharifi MIT

Gretchen Kinder Plastic Design Corporation

Darin Latimer Danaher

Vincent Lindner Opko Diagnostics

Andrew Lynn Fluidic Analytics

Selim Tanriverdi UMASS Medical School

Stu Jacobson DEKA Research and Development

Roshan Kumar HiFiBio

Tom O’Dwyer Analog Devices

Jerzy Olejnik Qiagen

Maxime Drobot Dolomite

Robert Pelletier Fluigent

Anne Le Nel Fluigent

Quanshang Paul

Lu Pasciuto

Instrumentation Lab MIT

Andy Racher Lonza

Florence Rivera CEA

Ken Robbins Novartis Institute

Dayanand Saini Cal Stat Uni Bakersfield

Alexis

Sauer-Budge

Fraunhofer IPT

Andrew Sheridan Qiagen

Ward Solar Labcyte

Alexios Tzannis IMT

Claudia Skazik-Voogt

Fraunhofer IPT

Thomas Umundum Stratec

Theodor Veres National Research Council of Canada

David Walsh MIT-Lincoln Laboratory

Andrew Hansong

Wheble Zeng

Du-Pont Instrumentation Lab

Victor Zhimov Semiconductor Research Corp

Table-Top Exhibits (in the Networking Area)

MFManufacturing project is the European initiative for the standardization and manufacturability of complex micro-fluidic (MF) devices. The project has been accepted by the ENIAC Joint Undertaking (JU), a public-private partnership focusing on nanoelectronics that brings together ENIAC Member/Dutch, German, French and United Kingdom States, the European Commission, and AENEAS (an association representing European R&D actors in this field). The objective is to bring the manufacturing of microfluidic devices to the same level of maturity and

industrialization of electronic devices, enabling them to address more widely in the healthcare needs. Electronic devices, which have been on the market for many years, have benefited from the long going standardization of electronic components, and were therefore easily integrated in the production process of the major foundries.

Established in 2005 as the world’s first microfluidic application centre, Dolomite focused

on working with customers to turn their concepts for microfluidic applications into reality.

Today, Dolomite is the world leader in solving microfluidic problems. With offices in the

UK, US and Japan, and distributors throughout the rest of the world, our clients range from

universities developing leading-edge analytical equipment, to manufacturers of chemical,

life sciences and clinical diagnostics systems.

Dolomite’s key strength lies in offering a complete service to customers from problem conceptualisation

and feasibility testing through to full instrument design and development. By Productizing Science™, we

have enabled customers around the world to develop more compact, cost-effective and powerful

instruments.

Dolomite also offers a Microfluidic Consultancy to develop a variety of versatile, complex and cutting edge

custom devices, available in exceptionally short lead times. Whatever your microfluidic requirements and

application, Dolomite is the right partner with the right expertise!

For more information please contact us on +44 (0)1763 242491, info@dolomite-microfluidics.com or visit our website www.dolomite-microfluidics.com.

Fluidic Analytics develops next generation tools for protein science. Our fundamentally new steady-state laminar flow platform allows proteins to be characterised in solution, under native conditions, quickly, cost-effectively and accurately. This platform brings together–on a single disposable chip–all of the fundamental steps of protein analysis, delivering a “sample in – data out” workflow that is rapid, simple and involves minimal sample preparation. Our technology looks to facilitate studies that distinguish proteins in simple solutions, cell lysates, or even complex mixtures, like blood plasma, by

simultaneously and sensitively measuring their key properties such as concentration, size, molecular weight and charge. And because our technology works best in extremely small volumes under physiological conditions, even highly complex protein solutions will be characterised rapidly, in small sample volumes and without extensive sample preparation.

The Fluidic Analytics platform characterises the properties of biomolecules and their interactions using novel approaches enabled by microfluidics. Our platform analyses proteins in solution under native conditions, obviating the need for tagging or labelling proteins before analysis. Measurements are conducted in label-free aqueous conditions at physiological pH, meaning that proteins and their interactions are assayed in their native conformations and without artefacts introduced by bulky tags or surface interactions. Applications of our platform include rapid size and concentration measurements, the detection of folding/unfolding, binding events, oligomerization, or aggregation, and binding constant determination.

The versatility of our platform and its compatibility with physiological conditions and native states give our technology the potential to make it easier, more accessible and more accurate to characterise the key characteristics of proteins that make our biological world function.

Since 2006, Fluigent has developed, manufactured and commercialized innovative microfluidic flow control and fluid handling solutions for laboratories, research units and industrials around the world. By providing full control of your microfluidic systems through pressure, flow and electrical

monitoring, Fluigent technologies provide high end solutions for all your microfluidic, lab-on-a-chip and cellular/biological applications (droplet-based drug testing, chromatography, cell perfusion, Organ-On-A-Chip, flow chemistry, cells and parasites separation, dielectophoresis, highly viscous fluids and liquid air manipulations, gene expression analysis in microdroplet, etc). Fluigent has pioneered the market of pressure-driven flow controllers for microfluidic applications and low volume fluid handling. The products are based on the patented FASTAB technology optimizing stability and responsiveness of the flow inside your microfluidic systems. In addition to the FASTAB technology, Fluigent owns or licenses a portfolio of worldwide patents covering its core technologies in microfluidic flow control, Lab-on-a-chip devices, diagnostics and life science analysis (cell capture, etc).

Foundry for the design and production of micro-optical and microfluidic components

Employees: 105 Operating area: 3000 m2 Clean room area: 1300 m2 (ISO 14644-1, class 5 and 6) Export ratio: > 90% Certification: ISO 9001:2008 (ISO 13485 as of the end of 2017) Registered office: Greifensee (Zurich), Switzerland

THE FUTURE OF SCIENCE IS SOUND

Our innovations have enabled our customers to enhance personalized medicine programs, streamline DNA/RNA diagnostic testing, optimize drug discovery pipelines and accelerate life science research. Labcyte customers have published papers in

peer-reviewed journals and received patents that clearly demonstrate discoveries and results that would have been impossible with traditional liquid-handling approaches — at a fraction of the cost.

Plastic Design Corporation has been a pioneer in the emerging microfluidics landscape. Having over 10 years of experience in this breakthrough technology makes us an established leader in the field. We are proud to have assisted multiple projects from inception to high volume production. PDC has proven its capabilities to meet, maintain, and repeat your design features with consistency and accuracy Cyclo Olephin Polymer (COP) is our specialty. COP provides the best attributes of glass with the ability to cost effectively reproduce highly detailed features. We also have also worked extensively with Polycarbonate, Styrene, and Polyporpylene.

The deepest mysteries of disease and other biological processes – the answers you seek – are encoded in the building blocks of life, DNA. Yet the work of learning what these molecules can tell you is quite a journey, and we at QIAGEN understand the challenges associated with this quest.

Our commitment is to enable you, like more than 500,000 customers around the world, to quickly and reliably reach your goal of useful, actionable insights. To this end, QIAGEN offers you innovative solutions that cover every single step along this

journey – not just technologies, but bridges from samples to insights. As you advance to new frontiers, QIAGEN also advances – and this website’s updated look and feel reflects our end-to-end commitment to your journey.

Sample to Insight means QIAGEN offers you the industry’s most reliable sample technologies, because samples matter to your success. Our top-quality assays and panels enable you to accurately analyze and identify diseases and genetic variations. Our bioinformatics software and curated knowledge bases transform your raw data into relevant, actionable findings. And our automation solutions provide you seamless and cost-effective workflows. Sample to Insight.

The insights you gain may lead to one small step or a giant leap forward for science and healthcare. Partnering with QIAGEN, your work can make a difference!

Logistics:

Delegates are responsible for making their own travel and

accommodation arrangements. Please tell us how you plan to travel and

where you will be staying so we can offer taxi/transfer shares. The

information below will facilitate this.

Overview:

FluidicMEMs Reception Meeting Venue Airport

Venue for Joint Reception with FluidicMEMS

700 Main Street

Cambridge, MA 02139

MF8 Meeting Location: Open Meeting (June 23) Closed Meeting (June 22)

Recommended Hotels:

Hotels in Cambridge MA are >>expensive<< We list a few below but for those on a more limited budget we

recommend taking the RED LINE towards Alewife where much more attractive offers can be found.